ProfessorsProfessors of Quinnipiac UniversityJennifer Gerarda Brown

Jennifer Gerarda Brown

Quinnipiac University

H-index: 21

North America-United States

About Jennifer Gerarda Brown

Jennifer Gerarda Brown, With an exceptional h-index of 21 and a recent h-index of 10 (since 2020), a distinguished researcher at Quinnipiac University, specializes in the field of Dispute Resolution, LGBT Equality, Lawyers' Professional Responsibility.

His recent articles reflect a diverse array of research interests and contributions to the field:

Preclinical Development of Antibody–Drug Conjugates

Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer

Preclinical evaluation of IMGC936, a next-generation maytansinoid-based antibody–drug conjugate targeting ADAM9-expressing tumors

Preclinical development of MGC018, a duocarmycin-based antibody–drug conjugate targeting B7-H3 for solid cancer

Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase β to Augment Mitochondrial Function and Prevent Neurodegeneration

Jennifer Gerarda Brown Information

University	Quinnipiac University
Position	Dean and Professor of Law
Citations(all)	1883
Citations(since 2020)	443
Cited By	1460
hIndex(all)	21
hIndex(since 2020)	10
i10Index(all)	35
i10Index(since 2020)	10
Email	Access Email
University Profile Page	Quinnipiac University
Google Scholar	View Google Scholar Profile

Jennifer Gerarda Brown Skills & Research Interests

Dispute Resolution

LGBT Equality

Lawyers' Professional Responsibility

Top articles of Jennifer Gerarda Brown

Title	Journal	Author(s)	Publication Date
Preclinical Development of Antibody–Drug Conjugates		Jennifer G Brown Deryk Loo Kurt Stahl	2024/1/1
Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer	Cancer Research	Juniper A Scribner Jennifer G Brown Thomas Son Linda Jin Carroll McKenzie ...	2024/3/22
Preclinical evaluation of IMGC936, a next-generation maytansinoid-based antibody–drug conjugate targeting ADAM9-expressing tumors	Molecular Cancer Therapeutics	Juniper A Scribner Stuart W Hicks Kerstin W Sinkevicius Nicholas C Yoder Gundo Diedrich ...	2022/7/5
Preclinical development of MGC018, a duocarmycin-based antibody–drug conjugate targeting B7-H3 for solid cancer	Molecular Cancer Therapeutics	Juniper A Scribner Jennifer G Brown Thomas Son Michael Chiechi Pam Li ...	2020/11/1
Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase β to Augment Mitochondrial Function and Prevent Neurodegeneration	Molecular neurobiology	Ali Saleh Mohammad Golam Sabbir Mohamad-Reza Aghanoori Darrell R Smith Subir K Roy Chowdhury ...	2020/6